Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on January 23, 2008
J Am Soc Nephrol 19: 329-338, 2008
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007040510

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2007040510v1
19/2/329    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, Y.
Right arrow Articles by Noble, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, Y.
Right arrow Articles by Noble, N. A.

BASIC RESEARCH

A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy

Yufeng Huang*, Wayne A. Border*, Ling Yu*, Jiandong Zhang*, Daniel A. Lawrence{dagger} and Nancy A. Noble*

* Fibrosis Research Laboratory, Division of Nephrology, University of Utah School of Medicine, Salt Lake City, Utah; and {dagger} Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan

Correspondence: Dr. Nancy A. Noble, Fibrosis Research Laboratory, 391 Chipeta Way, Suite E, Salt Lake City, UT 84108. Phone: 801-581-4615; Fax: 801-585-0579; E-mail: Nancy.noble{at}hsc.utah.edu

Received for publication April 26, 2007. Accepted for publication October 17, 2007.

Plasminogen activator inhibitor-1 (PAI-1) has been implicated in renal fibrosis. In vitro, PAI-1 inhibits plasmin generation, and this decreases mesangial extracellular matrix turnover. PAI-1R, a mutant PAI-1, increases glomerular plasmin generation, reverses PAI-1 inhibition of matrix degradation, and reduces disease in experimental glomerulonephritis. This study sought to determine whether short-term administration of PAI-1R could slow the progression of glomerulosclerosis in the db/db mouse, a model of type 2 diabetes in which mesangial matrix accumulation is evident by 20 wk of age. Untreated uninephrectomized db/db mice developed progressive albuminuria and mesangial matrix expansion between weeks 20 and 22, associated with increased renal mRNA encoding {alpha}1(I) and (IV) collagens and fibronectin. Treatment with PAI-1R prevented these changes without affecting body weight, blood glucose, glycosylated hemoglobin, creatinine, or creatinine clearance; therefore, PAI-1R may prevent progression of glomerulosclerosis in type 2 diabetes.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. Zhang, N. A. Noble, W. A. Border, R. T. Owens, and Y. Huang
Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells
Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E810 - E819.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP